Related references
Note: Only part of the references are listed.Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2022)
Retinal toxicities of systemic anticancer drugs
Supriya Arora et al.
SURVEY OF OPHTHALMOLOGY (2022)
Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports
Niloofar Khoshnam-Rad et al.
ANTI-CANCER DRUGS (2022)
Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature
Chiara Demichelis et al.
NEUROLOGICAL SCIENCES (2021)
Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders
Cong-Cong Jia et al.
FUTURE MEDICINAL CHEMISTRY (2021)
Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update
Alice Nervo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms
Mariarita Laforgia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function
Lukasz Mielczarek et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
Yi Zhao et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Current and future status of JAK inhibitors
Donal P McLornan et al.
LANCET (2021)
Trends in kinase drug discovery: targets, indications and inhibitor design
Misty M. Attwood et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab Post Hoc Review of HAWK and HARRIER
Jordi Mones et al.
OPHTHALMOLOGY (2021)
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Sweet syndrome as an adverse reaction to tyrosine kinase inhibitors: A review
Jason J. Yang et al.
DERMATOLOGIC THERAPY (2021)
Neurotoxicity of antibodies in cancer therapy: A review
Erika Horta et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2020)
Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors
Qiang Shi et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2020)
Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: A case report and literature review
Eleanor Russell-Goldman et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2020)
Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
Xiaowei Liu et al.
THORACIC CANCER (2020)
A case of discoid lupus erythematosus because of palbociclib
Giulia Calabrese et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2020)
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
Jason Weatherald et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Henoch-schonlein Purpura (HSP) in a patient on Abemaciclib
Claudia Omarini et al.
BREAST (2020)
Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database
Celine Anquetil et al.
JOURNAL OF AUTOIMMUNITY (2020)
Pulmonary toxicity of systemic lung cancer therapy
Kathryn Long et al.
RESPIROLOGY (2020)
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
Ilaria Proietti et al.
CANCERS (2020)
Vogt-Koyanagi-Harada (VKH) syndrome: A new perspective for healthcare professionals
Yojana B. Patil et al.
JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE (2020)
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)
Liling Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome
Kate R. Secombe et al.
INTEGRATIVE CANCER THERAPIES (2020)
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib
Francesco Facchinetti et al.
INVESTIGATIONAL NEW DRUGS (2019)
Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis
Mariana M. Fachi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
Ayesha Murtuza et al.
CANCER RESEARCH (2019)
Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study
Lucie Cornet et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Inflammatory side effects of BRAF and MEK inhibitors
Anna G. Mackin et al.
MELANOMA RESEARCH (2019)
Properties of FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Clinical development of targeted and immune based anti-cancer therapies
N. A. Seebacher et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
PI3K isoforms in cell signalling and vesicle trafficking
Benoit Bilanges et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Jeff P. Sharman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy
Francesca Consoli et al.
PLOS ONE (2019)
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Ali S. Alzahrani
SEMINARS IN CANCER BIOLOGY (2019)
Drug-induced liver injury
Raul J. Andrade et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Management of toxicity to isoform α-specific PI3K inhibitors
S. E. Nunnery et al.
ANNALS OF ONCOLOGY (2019)
The Landscape of Atypical and Eukaryotic Protein Kinases
Georgi K. Kanev et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy
Carla Colombo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Case of alopecia induced by sorafenib, possible mechanism similar to alopecia areata
Yasuyuki Tanaka et al.
JOURNAL OF DERMATOLOGY (2018)
Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions
Frederic Castinetti et al.
ANNALES D ENDOCRINOLOGIE (2018)
Potential molecular targets of statins in the prevention of hepatocarcinogenesis
Ezequiel Ridruejo et al.
ANNALS OF HEPATOLOGY (2018)
Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing
Bruno C. Medeiros et al.
BLOOD REVIEWS (2018)
Dasatinib-induced pulmonary arterial hypertension
Nurgul Ozgur Yurttas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
Mario E. Lacouture et al.
CLINICAL COLORECTAL CANCER (2018)
Drug-associated pulmonary arterial hypertension
Michael McGee et al.
CLINICAL TOXICOLOGY (2018)
Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer
Motohiro Tamiya et al.
INVESTIGATIONAL NEW DRUGS (2018)
Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib
Joanie Pinard et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2018)
Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma
Takayuki Fusumae et al.
JOURNAL OF DERMATOLOGY (2018)
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
Ajai Chari et al.
LEUKEMIA & LYMPHOMA (2018)
Kinase-targeted cancer therapies: progress, challenges and future directions
Khushwant S. Bhullar et al.
MOLECULAR CANCER (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
Robert Roskoski et al.
PHARMACOLOGICAL RESEARCH (2018)
Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients
Melissa G. Lechner et al.
THYROID (2018)
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients
Claudia Omarini et al.
CANCER BIOLOGY & THERAPY (2018)
Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report
Sylvere Guillemois et al.
CLINICAL BREAST CANCER (2018)
Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics
Ruth A. Mitchell et al.
EXPERIMENTAL CELL RESEARCH (2018)
Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication
Hansang Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma
Panagiotis T. Diamantopoulos et al.
MELANOMA RESEARCH (2018)
Do We Know Jack About JAK? A Closer Look at JAK/STAT Signaling Pathway
Emira Bousoik et al.
FRONTIERS IN ONCOLOGY (2018)
Drug-induced uveitis
Ramana S. Moorthy et al.
CURRENT OPINION IN OPHTHALMOLOGY (2018)
Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis
Carlos Alves et al.
OPHTHALMIC RESEARCH (2017)
EGFR TKI combination with immunotherapy in non-small cell lung cancer
Myung-Ju Ahn et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)
Marta Perez-De-Lis et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Drug-induced liver injury: recent advances in diagnosis and risk assessment
Gerd A. Kullak-Ublick et al.
GUT (2017)
Drug-induced pulmonary arterial hypertension: a review
Lohit Garg et al.
HEART FAILURE REVIEWS (2017)
The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy
Fatima Ardito et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2017)
Retinal vein occlusions
A. Pierru et al.
JOURNAL FRANCAIS D OPHTALMOLOGIE (2017)
Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma
Carolien M. Beukhof et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Posterior reversible encephalopathy syndrome
Marlene Fischer et al.
JOURNAL OF NEUROLOGY (2017)
Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia
Hiroaki Tachi et al.
Journal of Thoracic Oncology (2017)
Effectiveness of erlotinib in Critical Care Unit in patients with non-small cell lung cancer with EGFR mutation
M. Dewolf et al.
REVUE DE PNEUMOLOGIE CLINIQUE (2017)
MEK inhibition and immune responses in advanced melanoma
Reinhard Dummer et al.
ONCOIMMUNOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
D. Arnold et al.
ANNALS OF ONCOLOGY (2017)
Pulmonary arterial hypertension induced by tyrosine kinase inhibitors
Jason Weatherald et al.
CURRENT OPINION IN PULMONARY MEDICINE (2017)
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going
A. Russo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Anticancer Drug-Induced Acute Kidney Injury
Hassan Izzedine et al.
KIDNEY INTERNATIONAL REPORTS (2017)
Pulmonary Manifestations of Acute Lung Injury More Than Just Diffuse Alveolar Damage
Kenneth T. Hughes et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)
PI3K signaling in cancer: beyond AKT
Evan C. Lien et al.
CURRENT OPINION IN CELL BIOLOGY (2017)
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia
K. A. Rogers et al.
LEUKEMIA (2016)
Dasatinib-Induced T-Cell-Mediated Colitis: A Case Report and Review of the Literature
Mohamed Shanshal et al.
ACTA HAEMATOLOGICA (2016)
Ocular toxicities of MEK inhibitors and other targeted therapies
N. Stjepanovic et al.
ANNALS OF ONCOLOGY (2016)
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
Paul M. Barr et al.
BLOOD (2016)
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Benjamin L. Lampson et al.
BLOOD (2016)
Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma
Juliette Eroukhmanoff et al.
BMC CANCER (2016)
Vascular Toxicities of Cancer Therapies The Old and the New - An Evolving Avenue
Joerg Herrmann et al.
CIRCULATION (2016)
Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
Rashmi R. Shah
DRUG SAFETY (2016)
Hepatotoxicity of targeted therapy for cancer
Kirsty Wai-Chung Lee et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension
Christophe Guignabert et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients
David J. Dorer et al.
LEUKEMIA RESEARCH (2016)
Systemic vasculitis associated with vemurafenib treatment Case report and literature review
Adrien Mirouse et al.
MEDICINE (2016)
The role of tyrosine kinase inhibitor Lapatinib in pulmonary hypertension
Yaser Alkhatib et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2016)
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
L. Paoluzzi et al.
CLINICAL SARCOMA RESEARCH (2016)
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System
Jorge Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib
Neil P. Shah et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Idelalisib-associated Enterocolitis Clinicopathologic Features and Distinction From Other Enterocolitides
Christine Y. Louie et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Idelalisib-associated Colitis Histologic Findings in 14 Patients
Anna-Sophie Weidner et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitorsaEuro
T. W. Chen et al.
ANNALS OF ONCOLOGY (2015)
Predictive and Prognostic Biomarkers for Patients Treated with Anti-EGFR Agents in Lung Cancer: A Systemic Review and Meta-Analysis
Ying Wang et al.
Asian Pacific Journal of Cancer Prevention (2015)
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
Samantha M. Jaglowski et al.
BLOOD (2015)
A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2015)
Ten things you should know about protein kinases: IUPHAR Review 14
Doriano Fabbro et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors
Pooja Ghatalia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials
Pooja Ghatalia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Anaplastic lymphoma kinase inhibitors
Ramona Crescenzo et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Management of pulmonary toxicity associated with targeted anticancer therapies
Laure-Anne Teuwen et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Distal Symmetric Polyneuropathy A Review
Brian C. Callaghan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Lymphocytic panniculitis: an algorithmic approach to lymphocytes in subcutaneous tissue
Carolyn J. Shiau et al.
JOURNAL OF CLINICAL PATHOLOGY (2015)
Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature
R. Moessner et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E. Coutre et al.
LEUKEMIA & LYMPHOMA (2015)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial
Animesh Pardanani et al.
JAMA ONCOLOGY (2015)
Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis
Ramy A. Abdelrahman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review
Yi Ling Teo et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Panniculitis in Patients Treated With BRAF Inhibitors: A Case Series
Bonita Choy et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2014)
Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib
Christina H. Choe et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2014)
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments
Claudia Omarini et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy
Roberto Iacovelli et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer
Akihiko Gemma et al.
CANCER SCIENCE (2014)
Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells
Elzbieta Gocek et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2014)
Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis
Wei-Xiang Qi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of Literature
Joichi Usui et al.
HUMAN PATHOLOGY (2014)
Pemphigus foliaceous-like reaction in a patient with chronic myeloid leukemia treated with the tyrosine kinase inhibitors nilotinib and dasatinib
Almudena Nuno-Gonzalez et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2014)
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
Antoni Ribas et al.
LANCET ONCOLOGY (2014)
VEGF-targeted cancer therapeutics - paradoxical effects in endocrine organs
Yihai Cao
NATURE REVIEWS ENDOCRINOLOGY (2014)
Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF) An 8-year Observational Study at a Single Center
Hassan Izzedine et al.
MEDICINE (2014)
RETINAL TOXICITIES OF CANCER THERAPY DRUGS Biologics, Small Molecule Inhibitors, and Chemotherapies
Catherine Y. Liu et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2014)
Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis
Wei-Xiang Qi et al.
TUMOR BIOLOGY (2014)
Risk Factors for Central and Branch Retinal Vein Occlusion: A Meta-Analysis of Published Clinical Data
Petr Kolar
JOURNAL OF OPHTHALMOLOGY (2014)
Uveitis in Patients With Late-Stage Cutaneous Melanoma Treated With Vemurafenib
Mikael Guedj et al.
JAMA OPHTHALMOLOGY (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature
Imane El Dika et al.
CASE REPORTS IN MEDICINE (2014)
Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer
Colin D. Weekes et al.
CLINICAL CANCER RESEARCH (2013)
Biologics-induced autoimmune diseases
Roberto Perez-Alvarez et al.
CURRENT OPINION IN RHEUMATOLOGY (2013)
Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
Rashmi R. Shah et al.
DRUG SAFETY (2013)
Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
Devron R. Shah et al.
DRUG SAFETY (2013)
Tyrosine Kinase Inhibitors and the Thyroid as both an Unintended and an Intended Target
Marion Vetter et al.
Endocrine Practice (2013)
Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment
Tadashi Nagai et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study
R. J. Schilder et al.
GYNECOLOGIC ONCOLOGY (2013)
Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan
Yuka Horiuchi-Yamamoto et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma
Leticia Alonso-Castro et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Drug-induced pulmonary arterial hypertension: a recent outbreak
David Montani et al.
EUROPEAN RESPIRATORY REVIEW (2013)
Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib
Sofia Jonsson et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
R. Sabatier et al.
ANNALS OF ONCOLOGY (2012)
FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication and the Patterns of Its Gene Sequence in 207 Chinese Patients With De Novo Acute Myeloid Leukemia
Ling Zhong et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2012)
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors
Gordana Vlahovic et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Proliferative glomerulonephritis with monoclonal IgM deposits without Waldenstrom's macroglobulinemia: case report and review of the literature
Mayumi Yahata et al.
CLINICAL NEPHROLOGY (2012)
Thyroid Dysfunction in Patients Treated with Tyrosine Kinase Inhibitors, Sunitinib, Sorafenib and Axitinib, for Metastatic Renal Cell Carcinoma
Makoto Daimon et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2012)
Vasculitis and panniculitis associated with vemurafenib
Roberto A. Novoa et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante et al.
LANCET ONCOLOGY (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers
Taher Abu-Hejleh et al.
CURRENT ONCOLOGY REPORTS (2012)
Ocular Complications After Anti-Vascular Endothelial Growth Factor Therapy in Medicare Patients With Age-Related Macular Degeneration
Shelley Day et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2011)
Hypothyroidism in Patients With Renal Cell Carcinoma Blessing or Curse?
Manuela Schmidinger et al.
CANCER (2011)
Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight
Ji Hye Min et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Treatment-Related Mortality With Bevacizumab in Cancer Patients A Meta-analysis
Vishal Ranpura et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression
Mariette H. W. Kappers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Drug-induced dysimmune demyelinating neuropathies
Joerg-Patrick Stuebgen
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Hematologic toxicities of small molecule tyrosine kinase inhibitors
Nicholas A. Barber et al.
TARGETED ONCOLOGY (2011)
Pulmonary toxicities from targeted therapies: a review
Nicholas A. Barber et al.
TARGETED ONCOLOGY (2011)
Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management
Rebecca L. Brown
TARGETED ONCOLOGY (2011)
Posterior reversible encephalopathy syndrome induced by anti-VEGF agents
Camille Tlemsani et al.
TARGETED ONCOLOGY (2011)
Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
Avital F. Barak et al.
HEMATOLOGY REPORTS (2011)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
Pleural effusions due to dasatinib
Anupama G. Brixey et al.
CURRENT OPINION IN PULMONARY MEDICINE (2010)
Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma
Shuichi Sato et al.
ENDOCRINE JOURNAL (2010)
Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
D. L. Richardson et al.
GYNECOLOGIC ONCOLOGY (2010)
Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Theo D. Kim et al.
THYROID (2010)
Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation
Hideaki Miyake et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients
Philipp Ivanyi et al.
WORLD JOURNAL OF UROLOGY (2010)
An Acute Hepatitis Resembling Autoimmune Hepatitis Occurring During Imatinib Therapy in a Gastrointestinal Stromal Tumor Patient
Sandra Aliberti et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2009)
Glivec (R) induced autoimmune hepatitis
F. Charier et al.
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE (2009)
A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib
Marinya Pongpudpunth et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2009)
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
Sanjaykumar Hapani et al.
LANCET ONCOLOGY (2009)
A case of lichen planus associated to treatment with imatinib
Zurine Martinez de Lagran et al.
MEDICINA CLINICA (2009)
OPTIC NEUROPATHY IN PATIENTS WITH GLIOBLASTOMA RECEIVING BEVACIZUMAB
J. H. Sherman et al.
NEUROLOGY (2009)
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
I. Tamaskar et al.
ANNALS OF ONCOLOGY (2008)
The clinical implications of sunitinib-induced hypothyroidism:: a prospective evaluation
P. Wolter et al.
BRITISH JOURNAL OF CANCER (2008)
Management of bevacizumab-associated bowel perforation: a case series and review of the literature
B. D. Badgwell et al.
ANNALS OF ONCOLOGY (2008)
Sunitinib and hypothyroidism
R. Cohen et al.
ANNALES D ENDOCRINOLOGIE (2007)
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
Deborah Mannavola et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer
Demosthenes Makris et al.
BMC CANCER (2007)
Gastrointestinal perforation due to bevacizumab in colorectal cancer
Muhammad Wasif Saif et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
Elaine Wong et al.
THYROID (2007)
Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma
Ruchdi K. Barakat et al.
ANNALS OF PHARMACOTHERAPY (2007)
Structural and functional diversity of the microbial kinome
Natarajan Kannan et al.
PLOS BIOLOGY (2007)
Imatinib-induced immune hepatitis: Case report and literature review
Enaam Al Sobhi et al.
HEMATOLOGY (2007)
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
Jayesh Desai et al.
ANNALS OF INTERNAL MEDICINE (2006)
Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine
J. W. B. de Groot et al.
ANNALS OF ONCOLOGY (2006)
Fulminant, but reversible interstitial pneumonitis associated with imatinib mesylate
Jen-Tsun Lin et al.
LEUKEMIA & LYMPHOMA (2006)
Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour
Alexandre Pariente et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2006)
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
M Ando et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Imaging of gefitinib-related interstitial lung disease: Multi-institutional analysis by the West Japan Thoracic Oncology Group
M Endo et al.
LUNG CANCER (2006)
Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: An analysis of risk factors and treatment outcomes in Okayama lung cancer study group
K Hotta et al.
CANCER JOURNAL (2005)
Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials
AB Tullo et al.
EYE (2005)
Gastrointestinal perforations associated with interleukin-2 administration
DM Heimann et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib
T Takano et al.
LUNG CANCER (2004)
Case 1. Nephrotic syndrome associated with gefitinib therapy
R Kumasaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
FDA drug approval summary: Gefitinib (ZD1839) (Iressa (R)) tablets
MH Cohen et al.
ONCOLOGIST (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Autoreactive CD8 T cells in organ-specific autoimmunity: Emerging targets for therapeutic intervention
RS Liblau et al.
IMMUNITY (2002)
Share Paper
